Study Introduction: Conducted as a double-blind, placebo-controlled trial, the research aimed to assess the effectiveness of VERISOL® collagen peptides in addressing key biophysical skin parameters associated with cutaneous aging. The study enlisted over 60 women aged 35-55, all with normal skin characteristics.
Study Design: Participants were divided into two groups—one receiving a daily intake of 2.5g VERISOL® collagen peptides and the other a placebo. The trial spanned 8 weeks, with measurements taken at crucial intervals—4 and 8 weeks into the study. Additionally, a 4-week washout period followed the completion of the trial.
Key Findings:
- The results revealed a noteworthy outcome in terms of skin elasticity.
- Those who consumed 2.5g of VERISOL® exhibited a substantial increase in skin elasticity compared to the placebo group at both the 4-week and 8-week intervals.
- Importantly, this positive impact on skin elasticity endured even during the subsequent 4-week washout phase, suggesting a sustained and enduring dermal physiological effect.
Conclusion: The study, authored by Proksch et al in 2014 and published in Skin Pharmacol Physiol (27:47-55), provides compelling evidence for the beneficial effects of specific collagen peptides, particularly VERISOL®, on enhancing human skin physiology.